HPV among Females of Reproductive Age Attending a Tertiary Institution in Port Harcourt, Nigeria
International Journal of Research and Reports in Gynaecology,
Aims: The study was aimed at determining HPV seroprevalence among females of reproductive age and identify the demographic/behavioural profile associated with the seroprevalence.
Study Design: Cross-sectional study.
Place and Duration of Study: O.B. Lulu-Briggs Health Centre, University of Port Harcourt, in Rivers State, Nigeria, from July 2013 to May 2014.
Methodology: Ninety-one females were included in this study. The age ranged from 15 to 45 years. Detection HPV infection was gotten using the ELISA and was performed according to the kit manufacturer’s stipulations. The demographic characteristics of the participants were obtained with a Performa designed for the study.
Results: Higher seropositivity of anti-HPV IgG antibodies occurred in the age group 18-25 years (18.2%) than other age groups (26-35 years, 4.1% and 36-45 years, 0.0%). The highest seronegativity (100.0%) occurred in the age group 36-45 years while the age group 18-25 years (81.8%) had the least. Higher seropositivity occurred in females with no formal education (33.3%) than primary (9.1%) secondary (3.8%) and tertiary education (0.0%). While higher seronegativity (100.0%) occurred in tertiary education compared to secondary (96.2%), primary (90.9%) and no education (66.7%). Higher seropositivity occurred among the married (27.3%) than the singles (1.2%). Higher seronegativity occurred among singles (98.8%) than the married (72.7%). Higher seropositivity occurred among other religions (4.9%) than Christianity (4.0%). Furthermore, Christians had higher seronegativity (96.0%) compared to other religions (95.1%).
Conclusion: The study clearly shows that although the seroprevalences are higher among younger females elsewhere in Nigeria, only 4.4% of the females had IgG antibodies to HPV-6, -11, -16 and -18 vaccine genotypes. It also established a high seronegativity among the females of reproductive age in Port Harcourt, Nigeria. To the best of our knowledge, this is the first documented report of high IgG seronegativity to HPV-6, -11, -16 and -18 vaccine genotypes in a higher institution in Port Harcourt, Nigeria. These findings reveal the susceptibility of a large population of females to infections with these four HPV genotypes in the University. With these findings, early screening and clinical evaluation for HPV-related manifestations are very imperative among females of reproductive age in Nigeria.
- HPV infection
- HPV-related manifestations
How to Cite
Syrjänen K, Shabalova I, Naud P, Kozachenko V, Derchain S, Zakharchenko S. et al. New Independent States of the Former Soviet Union and the Latin American Screening Study Research Groups. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. Int J Gynecol Cancer. 2009b;19:934-42.
Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int. J. Cancer. 2008:123(6):1344-9.
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, De Sanjose S, Bruni L, Tortolero. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia, Vaccine. 2008;26 Suppl(10):K1-16.
Muñoz N, Manalastas RJr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-57.
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 2010;202:1789-99.
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide. American Journal of Cancer. 2008;10(2):23-34.
Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A. et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British Journal of Cancer. 2004;90:638–645.
Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine. 2010;102(5A):3–8.
Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int. J. Cancer. 2009;125:2166-72.
Goncalves AK, Machado PRL, De Souza LC, Costa APF, Gimenes F, Consolaro ML. Detection of Immunoglobulin IgA and igg against human papillomavirus. Viral Immunology. 2014;27(9):1-7.
Louvanto K, Rintala MA, Syrjänen KJ, Grénman SE, Syrjänen SM. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish family HPV study. J. Infect. Dis. 2010a;202:436-44.
Louvanto, K., Syrjänen, K.J., Rintala, M.A., Grénman, S.E. and Syrjänen, S.M. (2010b): Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish family HPV study. J. Clin. Microbiol. 48:2665-71.
Banura C, Sandin S, Van Doorn LJ, Quint W, Kleter B, Wabwire-Mangen F. et al. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect. Agent Cancer. 2010;5:7.
Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect. Agent Cancer. 2011;6:11.
Ogoina D, Musa BO, Onyemelukwe GC. Human papillomavirus (HPV) infection is associated with HIV-1 infection and AIDS in HIV-infected adult patients from Zaria, Northern Nigeria. Pan African Medical Journal. 2013;15:38.
Okonko IO, Ofoedu V. Prevalence of IgG antibodies against human papillomavirus (HPV) type 6, 11, 16 and 18 virus-like particles in women of childbearing age in Port Harcourt, Nigeria. Journal of Immunoassay and Immunochemistry. 2015;36(06):622-638.
Okonko IO, Ofoedu V, Okerentugba PO, Frank-Peterside N. Seroepidemiology and high negativity of IgG antibodies against human papillomavirus (HPV) type 6, 11, 16 and 18 virus-like particles in women of childbearing age in Port Harcourt, Nigeria. Journal of Immunoassay and Immunochemistry. 2015;36(2):210-220.
Adekunle A, Sule WF, Oluwayelu DO. High Negativity of IgG Antibodies against Human Papillomavirus Type 6, 11, 16 and 18 Virus-like Particles in Healthy Women of Childbearing Age. Journal of Experimental and Integrated Medicine. 2014;4(1):37-41.
Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, Li C, Lorincz A, et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J. Infect. Dis. 1999;180:1316–1319.
Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T. et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int. J. Cancer. 2000;85: 206–210.
Castellsague X, Menendez C, Loscertales MP, Kornegay JR, Dos Santos F, Gomez-Olive FX, et al. Human papillomavirus genotypes in rural Mozambique. Lancet. 2001;358:1429–1430.
Gravitt PE, Kamath AM, Gaffikin L, Chirenje ZM, Womack S, Shah KV. Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe. Int. J. Cancer. 2002;100:729–732.
De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S. et al. Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. Sex. Transm. Dis. 2003;30:137–142.
World Health Organization (WHO). Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. WHO Press, Geneva, 2007.
Okolo C, Franceschi S, Adewole I, Thomas JO, Follen M, Snijders PJ, et al. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer. 2010;5(1):24.
Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. IARC HPV Prevalence Surveys Study Group.Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiology Biomarkers Previews. 2010;19:503-10.
Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. Int. J. Cancer. 2012;130:2111-2117.
Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P. et al.: Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int. J. Cancer. 2006;119:2612-9.
Merikukka M, Kaasila M, Namujju PB, Palmroth J, Kirnbauer R, Paavonen J. et al.: Differences in incidence and cooccurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer. 2011;128:1114-9.
Namujju PB. Occurrence of infections with multiple human papillomavirus (HPV) types among Finnish and Ugandan women. National Institute for Health and Welfare (THL). Research 80. 141 pages. Helsinki, Finland; 2012.
ISBN: 978-952-245-644-1 (printed),-952-245-645-8 (pdf)
De Vuyst H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S. et al. The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes Control. 2010;21(12):2309-13.
Firnhaber C, Evans D, Friedman-Khalili R, Williams S, Michelow P, Matlhagela K. et al. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana. J. Clin. Virol; 2011.
Marais DJ, Constant D, Allan B, Carrara H, Hoffman M, Shapiro S. et al. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J. Clin. Microbiol. 2008;46(2):732-9.
Epub 2007 Dec 12
Burd EM. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003;16:1-17.
Abstract View: 203 times
PDF Download: 178 times